Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Baxter
Dow
Boehringer Ingelheim
Healthtrust
Queensland Health
AstraZeneca
US Department of Justice
Medtronic

Generated: December 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,925,173

« Back to Dashboard

Title:Methods of using sustained release aminopyridine compositions
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Inventor(s): Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee: Acorda Therapeutics, Inc. (Ardsley, NY)
Filing Date:Apr 07, 2017
Application Number:15/482,426
Claims:1. A method of improving walking in a human multiple sclerosis patient in need thereof comprising: (a) measuring walking performance of the patient in a test administered prior to treatment of the patient with 4-aminopyridine; (b) treating the patient with 4-aminopyridine over a period of time; (c) measuring walking performance of the patient in a plurality of tests administered during said period of time; (d) selecting a patient who exhibits an improved walking performance during a majority of the plurality of tests administered during said period of time as compared to the test administered prior to treatment of the patient with 4-aminopyridine; and (e) orally administering to said patient selected in step (d) a sustained release composition of 10 milligrams of 4-aminopyridinetwice daily for a time period of at least two weeks.

2. The method of claim 1, wherein said test is a Timed 25 Foot Walk.

3. The method of claim 1, wherein said test is a 12-Item MS Walking Scale (MSWS-12).

4. The method of claim 1, wherein the time period in step (e) comprises 12 weeks.

5. The method of claim 1, wherein the treating in step (b) comprises orally administering a sustained release composition of 10 milligrams of 4-aminopyridine twice daily.

6. The method of claim 1, wherein the twice daily administering in step (e) is administering approximately every 12 hours.

7. The method of claim 1, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration to the patient.

8. The method of claim 1, wherein said sustained release composition is a tablet.

9. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising: (a) measuring walking speed of the patient in a test administered prior to treatment of the patient with 4-aminopyridine; (b) treating the patient with 4-aminopyridine over a period of time; (c) measuring walking speed of the patient in a plurality of tests administered during said period of time; (d) selecting a patient who exhibits an improved walking speed during a majority of the plurality of tests administered during said period of time as compared to the test administered prior to treatment of the patient with 4-aminopyridine; and (e) orally administering to said patient selected in step (d) a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks.

10. The method of claim 9, wherein said test is a Timed 25 Foot Walk.

11. The method of claim 9, wherein the time period in step (e) comprises 12 weeks.

12. The method of claim 9, wherein the treating in step (b) comprises orally administering a sustained release composition of 10 milligrams of 4-aminopyridine twice daily.

13. The method of claim 9, wherein the twice daily administering in step (e) is administering approximately every 12 hours.

14. The method of claim 9, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration to the patient.

15. The method of claim 9, wherein said sustained release composition is a tablet.

16. A method of improving walking in a human multiple sclerosis patient in need thereof comprising: (a) identifying the patient as a responder to treatment with 4-aminopyridine based on consistency of improvement in walking of the patient over time rather than magnitude of the improvement in walking in response to treatment with 4-aminopyridine, by a method comprising treating the patient with 4-aminopyridine over a period of time and repeatedly testing for consistency of improvement in walking of the patient over said period of time; and (b) orally administering to said patient identified in step (a) a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks.

17. The method of claim 16, wherein the improvement in walking is an increase in walking speed.

18. The method of claim 16, wherein the improvement in walking is measured by MSWS-12.

19. The method of claim 16, wherein the time period in step (b) comprises 12 weeks.

20. The method of claim 16, wherein the treating in step (a) comprises orally administering a sustained release composition of 10 milligrams of 4-aminopyridine twice daily.

21. The method of claim 16, wherein the twice daily administering in step (b) is administering approximately every 12 hours.

22. The method of claim 16, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration to the patient.

23. The method of claim 16, wherein said sustained release composition is a tablet.

24. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising: (a) identifying the patient as a responder to treatment with 4-aminopyridine based on consistency of improvement in walking speed of the patient over time rather than magnitude of increase in walking speed of the patient, in response to treatment with 4-aminopyridine, wherein the identifying comprises treating the patient with 4-aminopyridine over a period of time and repeatedly testing for consistency of improvement in the walking speed of the patient over said period of time, wherein said testing comprises measuring walking speed of the patient using a Timed 25 Foot Walk during said period of time; and (b) orally administering to said patient identified in step (a) a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks.

25. The method of claim 24, wherein the time period in step (b) comprises 12 weeks.

26. The method of claim 24, wherein the treating in step (a) comprises orally administering a sustained release composition of 10 milligrams of 4-aminopyridine twice daily.

27. The method of claim 24, wherein the twice daily administering in step (b) is administering approximately every 12 hours.

28. The method of claim 24, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration to the patient.

29. The method of claim 24, wherein said sustained release composition is a tablet.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Covington
Argus Health
Federal Trade Commission
Johnson and Johnson
Cipla
Teva
McKesson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.